Irritable Bowel Syndrome Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Irritable Bowel Syndrome pipeline constitutes 24+ key companies continuously working towards developing 24+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Irritable Bowel Syndrome Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Irritable Bowel Syndrome Market.
The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for sample report @ https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:
• Irritable Bowel Syndrome Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.
• Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others, are developing therapies for the Irritable Bowel Syndrome treatment
• Emerging Irritable Bowel Syndrome therapies such as - P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.
• In June 2025, AbbVie announced results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)
• In June 2025, Ardelyx announced results of an Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old
• In January 2025, the FDA granted tentative approval to Amneal Pharmaceuticals' 550 mg rifaximin tablets, referencing Bausch Health's Xifaxan, for treating adults with irritable bowel syndrome with diarrhea (IBS-D).
• In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a healthcare company specializing in gastrointestinal conditions, is set to present new subgroup analysis findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The analyses, derived from the primary endpoint of the pivotal Phase III STARS trial, assess the treatment effect of apraglutide based on baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The oral presentation, reveals that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as remnant bowel length. These results complement the previously reported positive outcomes from the pivotal Phase III trial.
• In February 2024, CinPhloro Pharma, part of the CinRx portfolio, is developing CIN-103 as an innovative treatment for irritable bowel syndrome with predominant diarrhea (IBS-D). The company announced that the first participant in its Phase 2 enviva study has been dosed. CIN-103, a novel phloroglucinol formulation designed for long-term use, is a non-opioid small molecule targeting multiple IBS-D mechanisms, including motility, secretion, pain, spasms, and inflammation.

Irritable Bowel Syndrome Overview
Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by chronic abdominal pain, bloating, and altered bowel habits. Irritable Bowel Syndrome affects millions globally, often impacting quality of life due to unpredictable symptoms. Irritable Bowel Syndrome is typically classified into subtypes based on predominant stool patterns: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and mixed type (IBS-M). Irritable Bowel Syndrome diagnosis relies on clinical criteria, such as the Rome IV criteria, since no definitive biomarker exists. Irritable Bowel Syndrome pathophysiology involves gut-brain axis dysfunction, visceral hypersensitivity, motility disturbances, and possible alterations in gut microbiota. Irritable Bowel Syndrome management includes dietary modifications like low FODMAP diets, stress reduction, and pharmacological interventions targeting specific symptoms. Irritable Bowel Syndrome treatment may involve antispasmodics, laxatives, antidiarrheals, or newer agents such as linaclotide and rifaximin. Irritable Bowel Syndrome prevalence is higher in women and often emerges before age 50. Irritable Bowel Syndrome research continues to explore novel therapeutics, probiotics, and neuromodulators to better control symptoms. Irritable Bowel Syndrome awareness is critical to reduce stigma and encourage patients to seek medical care. Irritable Bowel Syndrome significantly burdens healthcare systems due to frequent doctor visits and diagnostic tests. Irritable Bowel Syndrome prognosis is generally benign but symptoms can be chronic and relapsing.

Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:
• P4M01: P4Microbiome
• BMC426: Biomica
• ORP-101: OrphoMed
• INVA 8002: Invea Therapeutics, Inc.
• RQ-00310941: RaQualia Pharma
• RHB-102: RedHill Biopharma Ltd.
• Blautix: 4D pharma
• Rifamycin: SV-MMX Cosmo Pharmaceuticals

Route of Administration
Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type
Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Irritable Bowel Syndrome Pipeline Therapeutics Assessment
• Irritable Bowel Syndrome Assessment by Product Type
• Irritable Bowel Syndrome By Stage and Product Type
• Irritable Bowel Syndrome Assessment by Route of Administration
• Irritable Bowel Syndrome By Stage and Route of Administration
• Irritable Bowel Syndrome Assessment by Molecule Type
• Irritable Bowel Syndrome by Stage and Molecule Type

DelveInsight's Irritable Bowel Syndrome Report covers around 24+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies - https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:
Key companies developing therapies for Irritable Bowel Syndrome are - Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.

Irritable Bowel Syndrome Pipeline Analysis:
The Irritable Bowel Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Irritable Bowel Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.
• Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Irritable Bowel Syndrome drugs and therapies - https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Irritable Bowel Syndrome Pipeline Market Drivers
• Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, surge in the level of Unhealthy lifestyle are some of the important factors that are fueling the Irritable Bowel Syndrome Market.

Irritable Bowel Syndrome Pipeline Market Barriers
• However, complex diagnostic processes, lack of awareness and other factors are creating obstacles in the Irritable Bowel Syndrome Market growth.

Scope of Irritable Bowel Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others
• Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others
• Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
• Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers

Request for Sample PDF Report for Irritable Bowel Syndrome Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/irritable-bowel-syndrome-ibs-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Irritable Bowel Syndrome Report Introduction
2. Irritable Bowel Syndrome Executive Summary
3. Irritable Bowel Syndrome Overview
4. Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Irritable Bowel Syndrome Pipeline Therapeutics
6. Irritable Bowel Syndrome Late Stage Products (Phase II/III)
7. Irritable Bowel Syndrome Mid Stage Products (Phase II)
8. Irritable Bowel Syndrome Early Stage Products (Phase I)
9. Irritable Bowel Syndrome Preclinical Stage Products
10. Irritable Bowel Syndrome Therapeutics Assessment
11. Irritable Bowel Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Irritable Bowel Syndrome Key Companies
14. Irritable Bowel Syndrome Key Products
15. Irritable Bowel Syndrome Unmet Needs
16. Irritable Bowel Syndrome Market Drivers and Barriers
17. Irritable Bowel Syndrome Future Perspectives and Conclusion
18. Irritable Bowel Syndrome Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.